Bioenvision — Merger or Acquisition (September 2007)
24 slides from Bioenvision's merger presentation, Sep 19, 2007
Slide 1: Proposed Acquisition by Genzyme Corporation: Rationale and Valuation Perspectives
Proposed Acquisition by Genzyme Corporation September 2007 Rationale and Valuation Perspectives
Slide 2: Forward-looking statements
Certain forward looking statements are included in this presentation, including statements relating to a proposed transaction by and among Bioenvision Inc., Genzyme Corporation and Wichita Bio Corporation. These statements are made pursuant to the safe harbor provisions of the Private Securities Lit
Slide 3: Overview of Rationale
Overview of Rationale The transaction is in the best interests of stockholders The transaction allows Evoltra® to be developed and commercialized more rapidly toward the advancement of human health
Slide 4: Summary of Rationale
Summary of Rationale Process The transaction process was professional and comprehensive Negotiation The transaction price was determined to be the highest price then obtainable Cash Value Certainty There is certainty in the transaction value of $5.60 per share in cash Key Terms Our Board had the abi
Slide 5: Summary of Rationale (cont'd)
Summary of Rationale (cont’d) Valuation The transaction value is fair The transaction value represents a significant premium Alternatives There are significant operating risks to going it alone Incentives Board, management and shareholders’ incentives are aligned
Slide 6: Review
Transaction Review May 29, 2007 announcement $5.60 per share Two-step merger process Transaction valued Bioenvision at $345 million Step 1: Tender period closed July 10, 2007 Genzyme purchased 22% of shares on an as-converted basis Genzyme owns all of the preferred shares and the rights appurtenant
Slide 7: Company Overview
Company Overview Product focused biopharmaceutical company with approved cancer therapeutics Lead product Evoltra ® (clofarabine) Approved in E.U. for pediatric ALL with orphan drug exclusivity through 2016 Further clinical development opportunities Pending Adult AML elderly non-intensive Adult AML
Slide 8: BIVN Genzyme Co-Development Agreement
BIVN Genzyme Co-Development Agreement Formed March 12, 2001 with Ilex Oncology to co-develop, commercialize and market purine nucleoside analogues (i.e. clofarabine) Genzyme is successor-in-interest to Ilex U.S./Canada Rights* 100% of development costs in U.S./Canada 50% of approved development cost
Slide 9: Bidding Process
Transaction Rationale – Bidding Process Genzyme was the ONLY third party that made an offer which was not subsequently withdrawn. Since 2003, potential strategic alternatives explored with multiple parties Advisor engaged in 2003; subsequent advisor, UBS, engaged in mid-2005 Prior to 2007, over 20 p
Slide 10: Price Negotiation
Transaction Rationale – Price Negotiation Based on the results of our prior efforts and our extended arm’s-length negotiations with Genzyme, our board believed that the merger consideration represented the highest price per share that was then obtainable On April 11, 2007, the Company received an of
Slide 11: Key Term Negotiations
Transaction Rationale – Key Term Negotiations Since the public announcement on May 29, 2007, when it became public that the company was for sale for at $5.60 per share, we have not received ANY indication of interest from ANY third party regarding the sale of the Company. The transaction terms allow
Slide 12: Market Premium: LTM Price/Volume Performance
Transaction Rationale – Market Premium 08/15/06 LTM Price/Volume Performance 05/31/06 Receives European approval for Evoltra 09/18/06 Announces it is expanding into Japan and Southeast Asia for the clinical and commercial development of Evoltra 11/10/06 Announces the filing of a clinical trial autho
Slide 13: Market Premium
Transaction Rationale – Market Premium Price Implied ($/Share) Premium (%) 1 Day Prior to Announcement Date (5/25/07) 5.25 6.7 Unaffected Stock Price (5/15/07) (1) 3.35 67.2 1 Week Prior to Announcement Date (5/18/07) 4.00 40.0 1 Month Prior to Announcement Date (4/25/07) 3.75 49.3 30 Trading Day Av
Slide 14: Market Premium: Equity and Enterprise Value
Transaction Rationale – Market Premium @ Unaffected (US $mm, unless otherwise noted) Stock Price (1) @ Offer Price Share Price ($/Share) 3.35 $ 5.60 $ Diluted Shares Outstanding (Treasury Method) (2) 60.9 61.5 Equity Value (4) 204 $ 345 $ Plus: Debt - $ - $ Less: Cash (3) (48) $ (48) $ Enterprise Va
Slide 15: Financials and Forecast / Strategic Review
Transaction Rationale – Financials FYE 2007 Financial Performance Revenue of $19 million 40% sold to Cardiff into AML-16 trials Operating Loss of $37.6 million Company does not provide revenue guidance (1) Forecast / Strategic Review Independent third party consultant retained Review initiated and l
Slide 16: Strategic Review and Forecast
Transaction Rationale – Strategic Review and Forecast Fiscal Year End June 30, ($000,000s) 2017 2018 2019 2020 2021 2022 Net Sales 405.1 243.1 72.9 43.8 30.6 24.5 Total Royalties 2.6 0.7 0.7 0.7 0.7 0.7 Net Sales & Royalties 407.7 243.8 73.7 44.5 31.4 25.2 Total Op. Costs (before SRI Royalty and Pro
Slide 17: Revenue Multiples and Valuation
Revenue Multiples 4.8x 4.0x 2009 7.8x 6.8x 7.8x 6.4x 2008 12.4x 8.0x 12.4x 7.6x 2007 Implied BIVN Selected Companies (Mean) Implied BIVN Selected Companies (Mean) Comparable Transactions Comparable Companies Discounted Cash Flow Reference Range For Fair Price 22.5% 17.5% Offer $3.72 $5.33 $5.60 Tran
Slide 18: Street Expectations
Transaction Rationale – Street Expectations ($mm) Report Date Price Target Revenue EBITDA AG Edwards May 18, 2007 $9.00 284.1 139.9 UBS May 17, 2007 $13.00 207.6 57.1 CIBC World Markets May 9, 2007 $9.00 170.9 75.1 Rodman & Renshaw May 9, 2007 $12.00 199.5 72.1 Fortis Bank April 3, 2007 $3.00 107.6
Slide 19: Operational Risks of Going It Alone
Transaction Rationale – Operational Risks of Going It Alone Forecast assumes mid-2008 launch in adult AML elderly non-intensive indication in Europe Adult AML filing risk of non-randomized trial and request for AML-16 data Changing standards of care as additional drugs seek approval in hematological
Slide 20: Other Risks of Going It Alone
Transaction Rationale – Other Risks of Going It Alone Absence of transaction price to maintain floor on stock price Absence of buyout premium because market has information that no alternate bidders exist at this price Genzyme preferred stock rights Macro-environment: Small cap stocks in $100 millio
Slide 21: Market Reaction Drivers
Market Reaction Drivers 1 Source: 13-D filing of SCO Capital and affiliates dated June 6, 2007 and September 12, 2007. 13-D filings of Elliott Associates and affiliates dated August 10, 2007 and September 5, 2007. 2 Source: January 8, 2002 8-K filings of the Company, and Company records. 3 Source: F
Slide 22: Incentives: Board, management and shareholders aligned
Severance Stock Options Equity $ 2.6 $ 0.09 $ 7.9 Additional Value of Hypothetical $1 Increase in Purchase Price $ 3.3 $ 0.11 - Additional In-The-Money Value of Hypothetical $1 Increase in Purchase Price $ 14.3 $ 0.5 $ 44.1 Value at $5.60 $ 1.5 (3) $ 10.4 Executive Management (2) - $ 0.08 Other Inde
Slide 23: Conclusion
Conclusion 1 The transaction is the highest 2 The transaction value represents a substantial premium when analyzed using standard valuation metrics 3 The operating and other risks of not pursuing the transaction are significant The Board and management recommend voting for approval by proxy or in pe
Slide 24: Bioenvision
bioenvision